Comparative phenotypes of peripheral blood and spleen cells from cancer patients

•Phenotypic comparison of cells from the spleens and PB of cancer patients.•Increased frequency of CD8+PD-1+ T-cells in cancer patients’ spleens vs. PB.•Cytotoxic CD8+ T-Cells from cancer patients spleens have potential for ACT. Patients with resectable tumor, either in the body or the tail of the p...

Full description

Saved in:
Bibliographic Details
Published in:International immunopharmacology 2020-08, Vol.85, p.106655-106655, Article 106655
Main Authors: Cole, Kathryn E., Ly, Quan P., Hollingsworth, Michael A., Cox, Jesse L., Stromnes, Ingunn M., Padussis, James C., Foster, Jason M., Vargas, Luciano M., Talmadge, James E.
Format: Article
Language:English
Subjects:
Adult
Aged
Antigens
Blood
Cancer
CD223 antigen
CD8 antigen
Cell activation
Effector cells
Exhaustion
Female
Flow cytometry
Humans
Immunological memory
Lymphocytes
Lymphocytes T
Male
Markers
Memory cells
Middle Aged
Mucin
Neoplasms - blood
Neoplasms - immunology
Pancreas
Pancreatic cancer
PD-1 protein
Peripheral blood
Phenotype
Phenotypes
Programmed Cell Death 1 Receptor - immunology
Spleen
Spleen - cytology
Spleen - immunology
Splenectomy
T-Lymphocytes - immunology
Tumors
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Phenotypic comparison of cells from the spleens and PB of cancer patients.•Increased frequency of CD8+PD-1+ T-cells in cancer patients’ spleens vs. PB.•Cytotoxic CD8+ T-Cells from cancer patients spleens have potential for ACT. Patients with resectable tumor, either in the body or the tail of the pancreas, and cancer patients with a primary tumor adjacent to the splenic vasculature frequently undergo a splenectomy as standard of care during resection. The spleen provides an unutilized source of lymphocytes with potential utility for adoptive cellular therapy (ACT). In this report, spleen and peripheral blood (PB) cells from cancer patients were compared to one another and normal PB by flow cytometry with a focus on CD8+ T-cells, memory phenotype, and their relative expression of checkpoint proteins including program death ligand-1 (PD1). PD1 is both an activation marker for T-cells including antigen (Ag) specific responses, as well as a marker of T-cell exhaustion associated with co-expression of other checkpoint molecules such as lymphocyte activating gene-3 (LAG-3) and T-cell immunoglobulin and mucin domain containing-3 (TIM-3). In summary, the spleen is a rich source of CD8+PD1+ T-cells, with an 8-fold higher frequency compared to the PB. These CD8+ T-cells are predominantly central and transitional memory T-cells with associated effector phenotypes and low expression of TIM-3 and LAG-3 with potential utility for ACT”.
ISSN:1567-5769
1878-1705
DOI:10.1016/j.intimp.2020.106655